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Combined colistin and rifampicin therapy
for carbapenem-resistant Acinetobacter
baumannii infections: clinical outcome and
adverse events
In the February 2005 issue of Clinical Microbiology
and Infection, Michalopoulos et al. [1] concluded
that colistin should be considered as a treatment
option for critically-ill patients in the intensive
care unit with infections caused by multiresistant
Pseudomonas aeruginosa and Acinetobacter bauman-
nii.
We have observed previously that rifampicin is
active in vitro against A. baumannii, and this led us
to investigate the potential therapeutic role of this
antimicrobial agent in combination with polym-
ixin B, ampicillin–sulbactam and colistin [2–4].
The in-vitro activity of colistin was increased
significantly in the presence of rifampicin, and
this combination has been proposed for adminis-
tration in vivo [3,4]. However, no data are avail-
able on the in-vivo use of colistin–rifampicin
against A. baumannii. We would therefore like to
describe the clinical outcome of 14 patients
infected with carbapenem-resistant A. baumannii
who were treated with colistin–rifampicin, as well
as the adverse events of this combination.
Fourteen critically-ill patients (ten males) with
carbapenem-resistant A. baumannii infections,
mean age 49 years (median 47 years; range
22–89 years), in the intensive care units of three
urban hospitals in Rome, Italy were studied
(Table 1). All were receiving mechanical ventila-
tion (mean length of ventilation 28 days; median
16 days; range 5–148 days) and had pneumonia.
Carbapenem-resistant A. baumannii was isolated
from quantitative cultures of tracheal aspirate
from all 14 patients, and was also isolated from
the surgical sites of two patients and from the
blood of two other patients. All carbapenem-
resistant A. baumannii isolates were susceptible to
colistin according to the ATB TSE method (bio-
Me´rieux, Marcy l’Etoile, France). Intravenous
colistin sulphomethate sodium, 2 MU three-
times-daily, adjusted for creatinine clearance,
and intravenous rifampicin, 600 mg once-daily,
were administered for a mean of 12 days (median
12 days; range 2–24 days). Five of ten patients
with ampicillin–sulbactam-susceptible carbape-
nem-resistant A. baumannii also received intra-
venous ampicillin–sulbactam. Deterioration in
renal function (creatininaemia of up to
2.8 mg ⁄dL) was observed in only one patient,
who did not need renal replacement therapy. No
other adverse events occurred. Overall, seven
(50%) of 14 patients died, five from the Acinetob-
acter infection, one from Pseudomonas ventilator-
associated pneumonia, and one from methicillin-
resistant Staphylococcus aureus bloodstream infec-
tion. Three patients experienced a relapse of their
Table 1. Acinetobacter baumannii infections in 14 critically-ill patients
Patient
no.a
Gender
(M ⁄ F)
Age
(years)
Acinetobacter
infection
Antibiotic
therapy Outcome
Antibiotic adverse
events
1 M 64 VAP C + R Recovered None
2 F 89 VAP C + R Acinetobacter VAP
and candidaemiab
None
3 M 73 VAP C + R Pseudomonas VAPb
Cleared Acinetobacter
Increase of
creatininaemia
2.8 mg ⁄dL
4 M 25 VAP, BSI C + R + A ⁄ S Recovered None
5 F 36 VAP C + R Recovered None
6 M 26 VAP C + R + A ⁄ S Recovered None
7 F 65 VAP C + R Recovered None
8 M 23 VAP C + R + A ⁄ S Recovered None
9 M 26 VAP, BSI C + R + A ⁄ S Acinetobacter
septic shockb
None
10 M 83 VAP C + R Acinetobacter
septic shockb
None
11 M 22 VAP C + R Recovered None
12 M 58 VAP, SSI C + R + A ⁄ S MRSA BSIb
Cleared Acinetobacter
None
13 M 65 VAP C + R Acinetobacter VAPb None
14 F 30 VAP, SSI C + R + A ⁄ S Acinetobacter VAPb None
BSI, bloodstream infection; VAP, ventilator-associated pneumonia; SSI, surgical site infection; C, colistin; R, rifampicin; A ⁄ S, ampicillin–sulbactam.
aPatients 1–3 had Acinetobacter resistant to carbapenems, aminoglycosides and ampicillin–sulbactam; patient 4 had Acinetobacter resistant to carbapenems and amikacin,
intermediately resistant to ampicillin–sulbactam, and sensitive only to gentamicin; patients 5–8 had Acinetobacter resistant to carbapenems and amikacin, and sensitive to
gentamicin and ampicillin–sulbactam; patients 9–14 had Acinetobacter resistant to carbapenems and aminoglycosides, and sensitive to ampicillin–sulbactam; all isolates were
sensitive to colistin.
bDied.
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
Acinetobacter infection, and received a second
course of colistin–rifampicin; two of these patients
died (one from carbapenem-resistant A. baumannii
ventilator-associated pneumonia and candidae-
mia, and the other from Pseudomonas ventila-
tor-associated pneumonia). Thus, therapy with
colistin–rifampicin, and with ampicillin–sulbac-
tam in case of susceptibility to this combination,
resulted in microbiological clearance of carbape-
nem-resistant A. baumannii infection in nine (64%)
of 14 critically-ill patients, with limited side-
effects. Although the limited number of patients,
and the lack of a control group, in this series does
not allow a definite conclusion, it seems that the
combination of colistin and rifampicin may be an
innovative therapeutic option for consideration in
the treatment of severe infections caused by
carbapenem-resistant A. baumannii.
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Occurrence of chlamydial cervicitis in
Upper Silesia, Poland
The recent article in Clinical Microbiology and
Infection by Kese et al. [1] described a prevalence
of Chlamydia trachomatis infection of 19.5% in
male partners and of 10.7% in female partners
attending two sexually transmitted disease clinics
in Slovenia. The study used two diagnostic
methods for the detection of C. trachomatis,
namely the MicroTrak direct fluorescent antibody
test, followed by the Amplicor PCR assay if the
direct fluorescent antibody results were inconclu-
sive. The results of the study supported the
implementation of routine screening for C. tracho-
matis genital infection among male and female
patients aged < 30 years who attend sexually
transmitted disease clinics in Slovenia.
It is well-known that the level of chlamydial
cervicitis decreases quickly in countries where
routine screening for C. trachomatis is mandatory
[2,3]. In Poland, routine screening for C. tracho-
matis is not yet provided. Our own experience in
Upper Silesia (south Poland; population c. 5
million) demonstrated a chlamydial aetiology for
cervicitis in 173 (49.3%) of 351 sexually active
women (mean age 31.7 ± 6.82 years) attending
the Department and Clinic of Gynaecology and
Endocrinology at the Medical University of
Silesia, Katowice, between 2001 and 2004. All
351 women had symptoms of cervicitis, i.e.,
mucopurulent endocervical discharge and ⁄ or
‡ 30 neutrophils in a ·1000 field on the cervical
Gram stain, and ⁄ or bleeding. C. trachomatis was
detected by the direct immunofluorescence assay
(bioMe´rieux, Marcy l’Etoile, France), performed
according to the manufacturer’s instructions.
There was a significant difference between the
prevalence of C. trachomatis in Katowice (49.3%)
and the study of Kese et al. (10.7%) [1]. However,
Kese et al. [1] studied patients without clinical
symptoms of cervicitis attending sexually trans-
mitted disease clinics, while the Katowice study
only included patients with clinical symptoms of
cervicitis. In addition, there were differences in
the methods used for the detection of C. tracho-
matis. The direct immunofluorescence assay is a
rapid assay, but is less sensitive than the nucleic
acid amplification techniques, which are accep-
ted currently as the standard for diagnosis of
C. trachomatis infection and which were used by
Kese et al. [1] when inconclusive results were
obtained with the direct fluorescent antibody test.
Nucleic acid amplification techniques demon-
strate a sensitivity and specificity of 56–100%
and > 99%, respectively, in comparison with cell
culture [4]; in contrast, the reported sensitivity
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